Clinical Trials
64 trialsA Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
CLOVER
Fudan University
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
National Cancer Institute, Naples
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NSABP Foundation Inc
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
Sun Yat-sen University
Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
Göteborg University
Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University
AdRad
Scandinavian Prostate Cancer Group
Concurent Chemoradiotherapy in Head and Neck Cancers
Assiut University
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
Zhejiang Cancer Hospital
EPIC
University of Turin, Italy
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
Sun Yat-sen University
CAMELLIA
ChineseAMS
A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer
Henan Cancer Hospital
Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
West China Hospital
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
OITROLC
Sichuan Cancer Hospital and Research Institute
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
Fudan University
TNT
Institute of Cancer Research, United Kingdom
Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Guilin Medical University, China
ACCN
Zhejiang Cancer Hospital
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NSABP Foundation Inc
Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
Shanghai University of Traditional Chinese Medicine
NNBC3-Europe
Martin-Luther-Universität Halle-Wittenberg
Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
China Breast Cancer Clinical Study Group
PERS
Sun Yat-sen University
IRCNPC
Zhejiang Cancer Hospital
Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients
Sun Yat-sen University
Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer
Air Force Military Medical University, China
Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer
Guangdong Association of Clinical Trials
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB
Xinjiang Medical University
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
National Cancer Institute (NCI)
Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)